Get started
Author

Dimitar Tonev

Observed name: D Tonev
ORCID: 0000-0003-0142-318X
Observed ORCID: 0000-0003-0142-318X
OpenAlex ID: A5089948093
The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19
2022 · ACTIV-3/TICO Study Group, Angela J. Rogers, et al. · Annals of Internal Medicine · 60
PDF
Galectin-3: therapeutic targeting in liver disease
2023 · Alison C. Mackinnon, Dimitar Tonev, et al. · Expert Opinion on Therapeutic Targets · 38
Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial
2025 · Elizabeth Shumbayawonda, Marika French, et al. · Communications Medicine · 23
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19
2024 · Neil R Aggarwal, Jacquie Nordwall, et al. · Clinical Infectious Diseases · 15
PDF
Single‑Dose Pharmacokinetics and Safety of the Oral Galectin‑3 Inhibitor, Selvigaltin (GB1211), in Participants with Hepatic Impairment
2024 · Vassilios Aslanis, Michael Gray, et al. · Clinical Drug Investigation · 9
The Effect of Multi-Parametric Magnetic Resonance Imaging in Standard of Care for Nonalcoholic Fatty Liver Disease: Protocol for a Randomized Control Trial
2020 · Dimitar Tonev, Elizabeth Shumbayawonda, et al. · JMIR Research Protocols · 6
PDF
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
2023 · Tomas O Jensen, Greg A Grandits, et al. · The Journal of Infectious Diseases · 4
PDF
P20 Effect of elafibranor on pruritus in primary biliary cholangitis: symptom severity and quality of life measurements from the phase III ELATIVE® trial
2024 · Andreas E Kremer, Kris V Kowdley, et al. · 1
746 Characterization of Magnetic Resonance-derived Biomarkers of Liver Health in a European Cohort With Metabolic Syndrome and Non-alcoholic Fatty Liver Disease: Interim Analysis of an Ongoing Prospective Trial (radical1)
2020 · Elizabeth Shumbayawonda, Sofia Mouchti, et al. · Gastroenterology · 1
Alkaline phosphatase and bilirubin as predictors of long-term outcomes in primary biliary cholangitis: A systematic literature review
2025 · Jörn Schattenberg, Oyinkan Solanke, et al. · Zeitschrift für Gastroenterologie
P25 Elafibranor efficacy in primary biliary cholangitis according to biochemical response criteria in the phase III ELATIVE® trial
2024 · Mark Sonderup, C Wendy Spearman, et al.
P21 Improvement in lipid profiles with elafibranor treatment in primary biliary cholangitis during the phase III ELATIVE® trial
2024 · Marlyn J Mayo, Nuno Antunes, et al.
THU-124 Population pharmacokinetics of elafibranor in healthy participants and patients with liver diseases: A pooled analysis of 17 clinical studies
2024 · Marion Dehez, Karl Brendel, et al. · Journal of Hepatology
THU-105 Improvement in lipid profiles with elafibranor treatment in primary biliary cholangitis during the phase III Elativetrial
2024 · Marlyn J. Mayo, Nuno Antunes, et al. · Journal of Hepatology
LBP-028 Effect of elafibranor on pruritus in primary biliary cholangitis: symptom severity and quality of life measurements from the phase III ELATIVE® trial
2024 · Andreas E. Kremer, Kris V. Kowdley, et al. · Journal of Hepatology
The clinical relevance of perioperative Factor XIII levels in open biliary surgery for obstructive jaundice
2015 · Dimitar Tonev
Efficacy and Safety of Intramuscular Administration of Dexketoprofen Versus Meloxicam for Short-term Inhospital Treatment of Exacerbated Gonarthrosis
2013 · Dimitar Tonev, Antoaneta A. Toncheva, et al. · Meditsinski Pregled / Medical Review
PIN53 COST EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN (RBV) FOR RE-TREATMENT OF HCV GENOTYPE I (Gl) PATIENTS WHO DID NOT RESPOND TO PREVIOUS HCV TREATMENT: A UK PERSPECTIVE
2009 · DM Jensen, P Marcellin, et al. · Value in Health
PDF
Works count: 18
Citation count: 157
H-index: 6
I10-index: 4
Year
Topic
Type